Turning Point Brands (TPB) opened 2026 with Q1 revenue of US$124.3 million and basic EPS of US$0.61, alongside net income from continuing operations of US$11.7 million, setting a clear reference point for how the year is starting to shape up. The company has seen quarterly revenue move from US$106.4 million in Q1 2025 to US$124.3 million in Q1 2026, while basic EPS over that span has ranged between US$0.43 and US$1.16, giving you a fuller view of how top line and per share earnings have tracked into this latest print. With trailing 12 month net margin at 11.5% versus 12.9% last year, the results put profitability in focus as investors weigh growth drivers against some compression at the bottom line.

See our full analysis for Turning Point Brands.

With the headline numbers on the table, the next step is to examine how this earnings profile lines up against the widely held narratives around growth, risk, and quality to reveal which stories hold up and which start to look overstretched.

Revenue Trend vs. Margin Pressure

• On a trailing 12 month basis, revenue is US$480.9 million and net income from continuing operations is US$55.4 million, which works out to an 11.5% net margin compared with 12.9% a year earlier.
• Analysts' consensus view highlights growth in higher margin Modern Oral and premium brands. However, the move from a 12.9% to 11.5% trailing margin shows that, even with these growth drivers, profitability is currently under some pressure.
  • Consensus commentary points to Modern Oral pouches reaching 26% of revenue and premium products like Zig Zag and Stoker's supporting margins, while the data here shows overall net margin sitting lower than last year.
  • This mix of expanding premium categories alongside a lower trailing margin captures the tug of war between growth investments, legacy segment headwinds, and the earnings profile investors are seeing in the numbers.

Earnings Growth Meets Rich Valuation

• Over the last 12 months, earnings grew 11.5% and are forecast in the data to grow about 10.3% annually, while the stock trades on a P/E of 31.5x versus a Global Tobacco industry average of 12.5x and a peer average of 28.9x.
• Critics highlight that the current valuation, including a DCF fair value of US$39.11 versus the US$90.22 share price and a 31.5x P/E, looks demanding even when set against the earnings growth backdrop and the analysts' price target of US$131.25.
  • The trailing 12 month earnings of US$55.4 million support the idea of growth in the business, but the DCF fair value being less than half of the current price gives numerical backing to the more cautious view.
  • At the same time, analysts in the dataset are expecting around 10.3% earnings growth and see room up to US$131.25, which sits well above the current US$90.22, so the risk reward debate here is largely about how comfortable you are with the premium multiple.

On these numbers, skeptics who focus on valuation will want to see why bulls still argue the story has room to run, and the full bearish breakdown sets out those concerns in more detail. 🐻 Turning Point Brands Bear Case

Quarterly EPS Bumps Against Long-Term Story

• Across the last five reported quarters, basic EPS moved between US$0.43 and US$1.16 per quarter, while trailing 12 month EPS sits at US$2.97 and analysts in the provided data expect earnings to reach US$72.1 million, or US$3.19 per share, by around April 2029.
• Consensus narrative leans bullish on the idea that growing Modern Oral and premium products plus supply chain improvements can support that long term EPS path. However, the quarterly EPS range from US$0.43 to US$1.16 and the analysts' need for a 54.4x P/E on those 2029 earnings to justify targets underline how much of the story depends on execution over time.
  • The trailing EPS of US$2.97 versus the US$3.19 figure referenced for 2029 shows only a modest step up, which sits in contrast to the requirement for the stock to trade on a materially higher multiple of 54.4x to meet the US$131.25 target.
  • For readers, that mix of lumpy quarterly EPS and a relatively small EPS move over several years, paired with a much higher implied future P/E, is a good prompt to stress test whether the growth assumptions in Modern Oral and other categories feel realistic.

If you want to see how other investors connect this EPS path, growth drivers, and valuation debate, it is worth reading the broader community take on TPB's story. 📊 Read the what the Community is saying about Turning Point Brands.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Turning Point Brands on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Strong opinions on both sides of this story already. Take a moment to review the numbers yourself and decide how the risk reward tradeoff looks for you with the help of 3 key rewards and 1 important warning sign

Explore Alternatives

TPB's rich valuation, compressed net margin and reliance on modest long term EPS growth expectations together raise questions about how much upside is already priced in.

If that premium price tag makes you cautious, compare it with companies that pair stronger value signals and quality fundamentals using the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.